Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release first quarter financial ... the close of the U.S. financial markets. The Company ... May 7, 2015 at 4:30 p.m. Eastern / 1:30 ... developments. For both "listen-only" participants and those ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Available ... at http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE ... and reactive skin while battling the weakening threat ... restorative cream is formulated with star ingredient GLYCOSEA, ... biotechnology in a complex of soothing minerals and ...
(Date:4/29/2015)... According to a new market research ... & Non-Portable), Component (Accelerometer, Proximity Probe, & Others), ... Mining, & Others), & Geography - Global Forecast ... reach $1,453.76 Million by 2020, at a CAGR ... and 92 figures spread through 205 pages and ...
(Date:4/29/2015)... April 29, 2015 Cambrex Corporation (NYSE: CBM ... released on Friday, May 1, 2015 before the market opens. ... Company will host a conference call to discuss the financial ... , Friday, May 1, 2015 at 8:30 ... 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... US Oncology, Inc ., the nation,s ... treatment and research network in the United States, ... quarter of fiscal 2010 on Thursday, Nov. 4. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) A conference ...
... HONG KONG, Oct. 7 /PRNewswire-Asia-FirstCall/ -- China Cord ... CO ), the first and largest cord blood ... authorization of the stock repurchase program on September 15, ... for approximately US$1.6 million through October 6, 2010 at ...
... Dendreon Corporation (Nasdaq: DNDN ) today announced ... 3, 2010 at 4:30 p.m. ET to review third quarter ... be obtained as follows: Time: , 4:30 PM ... 2010Dial-in: , 1-866-730-5769 (domestic) or +1-857-350-1593 (international); conference ...
Cached Biology Technology:US Oncology to Report 2010 Third Quarter Operating Results 2China Cord Blood Corporation Updates Status Regarding Share Repurchase Program 2Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results 2
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Research Institute have identified specific molecules in the brain ... brain stem cells, which, when activated, can transform into ... findings are published online this week in the Proceedings ... An earlier paper (published in the May issue ...
... of niacin (vitamin B3) in the liver, which should provide ... HDL-cholesterol levels in the blood and thus lower the risk ... levels, the mechanism of how it works has been mysterious, ... production. Recent work had uncovered that a component of ATP ...
... America (ESA) will hold its 93rd Annual Meeting Aug. ... now open to the press. The meeting will include ... the theme, "Enhancing ecological thought by linking research and ... open the meeting on Sunday, Aug. 3 with his ...
Cached Biology News: Brain stem cells can be awakened, say Schepens scientists 2Ecological Society of America announces its 93rd Annual Meeting 2Ecological Society of America announces its 93rd Annual Meeting 3
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... KLH-conjugated, synthetic peptide corresponding to ... mouse p19ARF. The epitope ... 62-75. Clone 5-C3-1. Quality ... immunoblot. Stability ...
Request Info...
Biology Products: